About Us

We are a global clinical-stage biotechnology company committed to developing novel vaccines and biologic therapeutic candidates to address the world’s most life-threatening diseases and public health threats. Our History can be traced back to June 2007, when Dr. Liang, our chairman and executive Director, established Sichuan Clover through GenHunter.


In June 2007,Sichuan Clover was established as a research laboratory.

In July 2016,Sichuan Clover entered into an agreement to establish and build 32,000 sqm commercial-scale cGMP biomanufacturing facility in Changxing, Zhejiang Province, China.

In December 2017,We completed the Series A Investment and raised approximately RMB62.8 million.

In June 2018,Our first patient was dosed with SCB-313 for treatment of cancer patients with malignant ascites in Phase 1 clinical trial.

In November 2019,We completed the Series B Investment and raised approximately RMB304.1 million.

In January 2020,We initiated development of SCB-2019 (CpG 1018/Alum), our COVID-19 vaccine candidate.

In April 2020,We obtained funding from and established collaboration with CEPI for SCB-2019 (CpG 1018/Alum).

In June 2020,We completed the Series B-2 Investment and raised approximately RMB171.8 million.

In June 2020,Our first participant was dosed with SCB-2019 (CpG 1018/Alum) in Phase I clinical trial.

In November 2020,CEPI extended partnership with us to fund up to US$328 million for SCB-2019 (CpG 1018/Alum) through global Phase 2 and Phase 3 clinical trial.

In December 2020,We announced positive Phase 1 data for SCB-2019 (CpG 1018/Alum), our COVID-19 vaccine candidates.

In February 2021,We completed the Series C Investment and raised approximately US$230 million.

In March 2021,We initiated SPECTRA, a pivotal global Phase 2/3 clinical trial evaluating SCB 2019 (CpG 1018/Alum) for vaccine efficacy and dosed the first participant at a clinical trial site located in the Philippines.